Research ExplorerPublicationsCarfilzomib, lenalidomide and dexamethasone followed by a se...

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

Standard

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT. / Tilmont, Rémi; Yakoub-Agha, Ibrahim; Eikema, Diderik-Jan; Zinger, Nienke; Haenel, Mathias; Schaap, Nicolaas; Arroyo, Concepcion Herrera; Schuermans, Christine; Besemer, Britta; Engelhardt, Monika; Kuball, Jürgen; Michieli, Mariagrazia; Schub, Natalie; Wilson, Keith M O; Bourhis, Jean Henri; Mateos, Maria Victoria; Rabin, Neil; Jost, Edgar; Kröger, Nicolaus; Moraleda, José M; Za, Tommaso; Hayden, Patrick J; Beksac, Meral; Mclornan, Donal; Schönland, Stefan; Manier, Salomon.

In: BONE MARROW TRANSPL, Vol. 58, No. 11, 11.2023, p. 1182-1188.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Tilmont, R, Yakoub-Agha, I, Eikema, D-J, Zinger, N, Haenel, M, Schaap, N, Arroyo, CH, Schuermans, C, Besemer, B, Engelhardt, M, Kuball, J, Michieli, M, Schub, N, Wilson, KMO, Bourhis, JH, Mateos, MV, Rabin, N, Jost, E, Kröger, N, Moraleda, JM, Za, T, Hayden, PJ, Beksac, M, Mclornan, D, Schönland, S & Manier, S 2023, 'Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT', BONE MARROW TRANSPL, vol. 58, no. 11, pp. 1182-1188. https://doi.org/10.1038/s41409-023-02048-7

APA

Tilmont, R., Yakoub-Agha, I., Eikema, D-J., Zinger, N., Haenel, M., Schaap, N., Arroyo, C. H., Schuermans, C., Besemer, B., Engelhardt, M., Kuball, J., Michieli, M., Schub, N., Wilson, K. M. O., Bourhis, J. H., Mateos, M. V., Rabin, N., Jost, E., Kröger, N., ... Manier, S. (2023). Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT. BONE MARROW TRANSPL, 58(11), 1182-1188. https://doi.org/10.1038/s41409-023-02048-7

Vancouver

Tilmont R, Yakoub-Agha I, Eikema D-J, Zinger N, Haenel M, Schaap N et al. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT. BONE MARROW TRANSPL. 2023 Nov;58(11):1182-1188. https://doi.org/10.1038/s41409-023-02048-7

Bibtex

@article{f9013f64e31d452bbcb117c3e3861f56,
title = "Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT",
abstract = "In the setting of a first relapse of multiple myeloma (MM), a second autologous stem cell transplant (ASCT) following carfilzomib-lenalidomide-dexamethasone (KRd) is an option, although there is scarce data concerning this approach. We performed a retrospective study involving 22 EBMT-affiliated centers. Eligible MM patients had received a second-line treatment with KRd induction followed by a second ASCT between 2016 and 2018. Primary objective was to estimate progression-free survival (PFS) and overall survival (OS). Secondary objectives were to assess the response rate and identify significant variables affecting PFS and OS. Fifty-one patients were identified, with a median age of 62 years. Median PFS after ASCT was 29.5 months while 24- and 36-months OS rates were 92.1% and 84.5%, respectively. Variables affecting PFS were an interval over four years between transplants and the achievement of a very good partial response (VGPR) or better before the relapse ASCT. Our study suggests that a relapse treatment with ASCT after KRd induction is an effective strategy for patients with a lenalidomide-sensitive first relapse. Patients with at least four years of remission after a frontline ASCT and who achieved at least a VGPR after KRd induction appear to benefit the most from this approach.",
keywords = "Humans, Middle Aged, Multiple Myeloma/drug therapy, Lenalidomide/pharmacology, Retrospective Studies, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Neoplasm Recurrence, Local/drug therapy, Dexamethasone/therapeutic use, Transplantation, Autologous",
author = "R{\'e}mi Tilmont and Ibrahim Yakoub-Agha and Diderik-Jan Eikema and Nienke Zinger and Mathias Haenel and Nicolaas Schaap and Arroyo, {Concepcion Herrera} and Christine Schuermans and Britta Besemer and Monika Engelhardt and J{\"u}rgen Kuball and Mariagrazia Michieli and Natalie Schub and Wilson, {Keith M O} and Bourhis, {Jean Henri} and Mateos, {Maria Victoria} and Neil Rabin and Edgar Jost and Nicolaus Kr{\"o}ger and Moraleda, {Jos{\'e} M} and Tommaso Za and Hayden, {Patrick J} and Meral Beksac and Donal Mclornan and Stefan Sch{\"o}nland and Salomon Manier",
note = "{\textcopyright} 2023. The Author(s).",
year = "2023",
month = nov,
doi = "10.1038/s41409-023-02048-7",
language = "English",
volume = "58",
pages = "1182--1188",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "11",

}

RIS

TY - JOUR

T1 - Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

AU - Tilmont, Rémi

AU - Yakoub-Agha, Ibrahim

AU - Eikema, Diderik-Jan

AU - Zinger, Nienke

AU - Haenel, Mathias

AU - Schaap, Nicolaas

AU - Arroyo, Concepcion Herrera

AU - Schuermans, Christine

AU - Besemer, Britta

AU - Engelhardt, Monika

AU - Kuball, Jürgen

AU - Michieli, Mariagrazia

AU - Schub, Natalie

AU - Wilson, Keith M O

AU - Bourhis, Jean Henri

AU - Mateos, Maria Victoria

AU - Rabin, Neil

AU - Jost, Edgar

AU - Kröger, Nicolaus

AU - Moraleda, José M

AU - Za, Tommaso

AU - Hayden, Patrick J

AU - Beksac, Meral

AU - Mclornan, Donal

AU - Schönland, Stefan

AU - Manier, Salomon

N1 - © 2023. The Author(s).

PY - 2023/11

Y1 - 2023/11

N2 - In the setting of a first relapse of multiple myeloma (MM), a second autologous stem cell transplant (ASCT) following carfilzomib-lenalidomide-dexamethasone (KRd) is an option, although there is scarce data concerning this approach. We performed a retrospective study involving 22 EBMT-affiliated centers. Eligible MM patients had received a second-line treatment with KRd induction followed by a second ASCT between 2016 and 2018. Primary objective was to estimate progression-free survival (PFS) and overall survival (OS). Secondary objectives were to assess the response rate and identify significant variables affecting PFS and OS. Fifty-one patients were identified, with a median age of 62 years. Median PFS after ASCT was 29.5 months while 24- and 36-months OS rates were 92.1% and 84.5%, respectively. Variables affecting PFS were an interval over four years between transplants and the achievement of a very good partial response (VGPR) or better before the relapse ASCT. Our study suggests that a relapse treatment with ASCT after KRd induction is an effective strategy for patients with a lenalidomide-sensitive first relapse. Patients with at least four years of remission after a frontline ASCT and who achieved at least a VGPR after KRd induction appear to benefit the most from this approach.

AB - In the setting of a first relapse of multiple myeloma (MM), a second autologous stem cell transplant (ASCT) following carfilzomib-lenalidomide-dexamethasone (KRd) is an option, although there is scarce data concerning this approach. We performed a retrospective study involving 22 EBMT-affiliated centers. Eligible MM patients had received a second-line treatment with KRd induction followed by a second ASCT between 2016 and 2018. Primary objective was to estimate progression-free survival (PFS) and overall survival (OS). Secondary objectives were to assess the response rate and identify significant variables affecting PFS and OS. Fifty-one patients were identified, with a median age of 62 years. Median PFS after ASCT was 29.5 months while 24- and 36-months OS rates were 92.1% and 84.5%, respectively. Variables affecting PFS were an interval over four years between transplants and the achievement of a very good partial response (VGPR) or better before the relapse ASCT. Our study suggests that a relapse treatment with ASCT after KRd induction is an effective strategy for patients with a lenalidomide-sensitive first relapse. Patients with at least four years of remission after a frontline ASCT and who achieved at least a VGPR after KRd induction appear to benefit the most from this approach.

KW - Humans

KW - Middle Aged

KW - Multiple Myeloma/drug therapy

KW - Lenalidomide/pharmacology

KW - Retrospective Studies

KW - Treatment Outcome

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Neoplasm Recurrence, Local/drug therapy

KW - Dexamethasone/therapeutic use

KW - Transplantation, Autologous

U2 - 10.1038/s41409-023-02048-7

DO - 10.1038/s41409-023-02048-7

M3 - SCORING: Journal article

C2 - 37543712

VL - 58

SP - 1182

EP - 1188

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 11

ER -